| scholarly article | Q13442814 |
| P356 | DOI | 10.1021/BI0508237 |
| P8608 | Fatcat ID | release_wp6qsbeesrhdvm4bqp22mktwji |
| P698 | PubMed publication ID | 16086583 |
| P50 | author | Miguel Calero | Q42620419 |
| Bernardino F. Ghetti | Q56863342 | ||
| P2093 | author name string | Alex E Roher | |
| Ruben Vidal | |||
| Masaki Takao | |||
| Leticia Miravalle | |||
| P433 | issue | 32 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 10810-10821 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Biochemistry | Q764876 |
| P1476 | title | Amino-terminally truncated Abeta peptide species are the main component of cotton wool plaques | |
| P478 | volume | 44 |
| Q27010785 | A window into the heterogeneity of human cerebrospinal fluid Aβ peptides |
| Q46320596 | APP/Aβ structural diversity and Alzheimer's disease pathogenesis |
| Q37684387 | Abundance of Aβ₅-x like immunoreactivity in transgenic 5XFAD, APP/PS1KI and 3xTG mice, sporadic and familial Alzheimer's disease |
| Q48335727 | Amyloid and intracellular accumulation of BRI2. |
| Q37247201 | Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions |
| Q30316057 | An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice |
| Q37342565 | Antibody responses, amyloid-beta peptide remnants and clinical effects of AN-1792 immunization in patients with AD in an interrupted trial |
| Q28480522 | BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system |
| Q40785358 | C-Terminal Threonine Reduces Aβ43 Amyloidogenicity Compared with Aβ42. |
| Q34814186 | Caspase-6 activation in familial alzheimer disease brains carrying amyloid precursor protein or presenilin i or presenilin II mutations |
| Q37627051 | Cerebrospinal Fluid Levels of Amyloid Beta 1-43 Mirror 1-42 in Relation to Imaging Biomarkers of Alzheimer's Disease |
| Q41971448 | Comparative pathobiology of β-amyloid and the unique susceptibility of humans to Alzheimer's disease |
| Q60492861 | Cu(II) binding to various forms of amyloid-β peptides. Are they friends or foes? |
| Q33942884 | Distinct glutaminyl cyclase expression in Edinger-Westphal nucleus, locus coeruleus and nucleus basalis Meynert contributes to pGlu-Abeta pathology in Alzheimer's disease |
| Q46257047 | Distinct spatiotemporal accumulation of N-truncated and full-length amyloid-β42 in Alzheimer's disease |
| Q38367860 | Extracellular vesicles in Alzheimer's disease: friends or foes? Focus on aβ-vesicle interaction |
| Q38693441 | Familial Presenilin Mutations and Sporadic Alzheimer's Disease Pathology: Is the Assumption of Biochemical Equivalence Justified? |
| Q33624303 | Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease |
| Q50602593 | Forgetful and robotic: tap on a gene! |
| Q36719050 | Generation of a novel murine model of Aβ deposition based on the expression of human wild-type amyloid precursor protein gene |
| Q34995785 | Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Aβ deposits in hippocampus via distinct cellular mechanisms |
| Q46330873 | Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology |
| Q30319332 | Glutaminyl cyclases from animals and plants: a case of functionally convergent protein evolution |
| Q37010838 | Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations |
| Q37301151 | Immunodominant epitope and properties of pyroglutamate-modified Abeta-specific antibodies produced in rabbits |
| Q26745928 | Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges |
| Q30489966 | Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model |
| Q35197124 | Isoglutaminyl cyclase contributes to CCL2-driven neuroinflammation in Alzheimer's disease |
| Q36600041 | Mass spectrometric characterization of brain amyloid beta isoform signatures in familial and sporadic Alzheimer's disease |
| Q48636044 | N-Terminal pyroglutamate formation of Aβ38 and Aβ40 enforces oligomer formation and potency to disrupt hippocampal long-term potentiation |
| Q48284125 | N-Terminally Truncated Amyloid-β(11-40/42) Cofibrillizes with its Full-Length Counterpart: Implications for Alzheimer's Disease. |
| Q33801986 | Neuropathology and amyloid-β spectrum in a bapineuzumab immunotherapy recipient |
| Q37069525 | Neuropathology of Autosomal Dominant Alzheimer Disease in the National Alzheimer Coordinating Center Database. |
| Q34575806 | Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice |
| Q34243914 | PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM |
| Q60530538 | Passive Aβ Immunotherapy: Current Achievements and Future Perspectives |
| Q36984142 | Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study |
| Q34127547 | Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model |
| Q98163701 | Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer's-like mouse models |
| Q38608487 | Phosphorylation of amyloid beta (Aβ) peptides - a trigger for formation of toxic aggregates in Alzheimer's disease. |
| Q39513749 | Potent amyloidogenicity and pathogenicity of Aβ43. |
| Q36481949 | Presenilin-1 280Glu-->Ala mutation alters C-terminal APP processing yielding longer abeta peptides: implications for Alzheimer's disease |
| Q34110227 | Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process |
| Q35879035 | Proteomic Profiling in the Brain of CLN1 Disease Model Reveals Affected Functional Modules. |
| Q36787240 | Proteomics of Alzheimer's disease: understanding mechanisms and seeking biomarkers |
| Q37461136 | Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases |
| Q30512697 | Pyroglutamate amyloid β (Aβ) aggravates behavioral deficits in transgenic amyloid mouse model for Alzheimer disease |
| Q37062829 | Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models |
| Q38176899 | Pyroglutamate-Modified Amyloid Beta Peptides: Emerging Targets for Alzheimer´s Disease Immunotherapy |
| Q36379339 | Recent advances in applying mass spectrometry and systems biology to determine brain dynamics. |
| Q38002193 | Relationships between the amyloid precursor protein and its various proteolytic fragments and neuronal systems |
| Q47703114 | Role of Amyloid Precursor Protein (APP) and Its Derivatives in the Biology and Cell Fate Specification of Neural Stem Cells |
| Q45937456 | Senile plaques and cerebral amyloid angiopathy in an aged California sea lion (Zalophus californianus). |
| Q46348872 | Structural and functional analyses of pyroglutamate-amyloid-β-specific antibodies as a basis for Alzheimer immunotherapy |
| Q34481815 | The Arctic AβPP mutation leads to Alzheimer's disease pathology with highly variable topographic deposition of differentially truncated Aβ |
| Q30418483 | The Psen1-L166P-knock-in mutation leads to amyloid deposition in human wild-type amyloid precursor protein YAC transgenic mice. |
| Q37994283 | The amyloid state of proteins in human diseases |
| Q91651861 | The amyloid-β degradation intermediate Aβ34 is pericyte-associated and reduced in brain capillaries of patients with Alzheimer's disease |
| Q34586360 | The pathogenic aβ43 is enriched in familial and sporadic Alzheimer disease |
| Q41774231 | Understanding co-polymerization in amyloid formation by direct observation of mixed oligomers |
| Q42714348 | Widespread white matter and conduction defects in PSEN1-related spastic paraparesis |
Search more.